Lipoprotein(a): A Lipoprotein Whose Time Has Come

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Cardiovascular disease (CVD) remains a primary cause of death globally.
• Despite effective low-density lipoprotein cholesterol (LDL-C) lowering therapies, residual CVD risk persists in many patients.
• Elevated lipoprotein(a) [Lp(a)] is an independent CVD risk factor and contributes to this residual risk.

Purpose of the Study:

• To review the role of lipoprotein(a) [Lp(a)] as a causal risk factor for cardiovascular disease (CVD), aortic stenosis, and peripheral arterial disease.
• To discuss the limitations of current therapeutic options for reducing Lp(a) levels.
• To highlight the need for targeted Lp(a)-lowering strategies.

Main Methods:

• Review of existing clinical trial data and scientific literature.
• Analysis of the causal relationship between Lp(a) and specific cardiovascular conditions.
• Discussion of current management strategies for elevated Lp(a).

Main Results:

• Elevated Lp(a) is a confirmed independent risk factor for CVD, aortic stenosis, and peripheral arterial disease.
• Current therapies primarily focus on managing other risk factors like LDL-C, with limited success in addressing Lp(a)]-driven risk.
• Existing treatment options for directly lowering Lp(a) are limited.

Conclusions:

• Lipoprotein(a) [Lp(a)] represents a significant, genetically determined risk factor for cardiovascular disease (CVD) and related conditions.
• Aggressively managing modifiable risk factors is the current approach, but its efficacy for Lp(a)]-related risk is debated.
• Targeted therapies aimed at directly reducing Lp(a) are under active investigation and are crucial for addressing residual CVD risk.